BRIDGEWATER, N.J. — The Food and Drug Administration has approved a number of applications for the generic version of Pfizer’s Lyrica (pregabalin). The FDA gave the green light to the following companies: Amneal, Alembic, Alkem, Dr. Reddy’s, InvaGen, MSN Laboratories, Rising Pharmaceuticals, Sciegen, and Teva. Amneal’s generic version of Lyrica (pregabalin capsules) will be available
STUTTGART, Germany — Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics. The ever increasing demand of high-quality biopharmaceutical therapies such as monoclonal antibodies requires more than ever highly efficient and robust production technologies.
JERUSALEM, Israel —Teva Pharmaceuticals announces the introduction and availability of clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5%. This product is AB rated and bioequivalent to Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Gel. Teva Pharmaceuticals USA, Inc. is a wholly-owned subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd., one of the leading pharmaceutical companies in the world. Teva
JERUSALEM — Teva Pharmaceutical Industries Ltd., today announced the launch of a generic version of Uceris (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. “The launch of generic budesonide extended-release tablets signals an important
NORTH WALES, Pa. — Teva Pharmaceuticals has introduced AB rated perphenazine tablets, USP. Perphenazine, the generic version of Trilafon, is indicated for mental/mood disorders including schizophrenia, the manic phase of bipolar disorder, and schizoaffective disorder. The medicine helps reduce confusion and anxiety, treating nausea and vomiting and allowing patients to participate in everyday life. It
GREENVILLE, N.C. — Mayne Pharma has completed its purchase of a package of generic drug products from Teva Pharmaceutical Industries Ltd. and Allergan plc. Mayne said Wednesday that under the $652 million deal, announced in late June, it takes ownership of 37 approved and five filed generic pharmaceutical products. The transaction was the largest generics
NEW YORK — The Federal Trade Commission has given its approval to two major pharma acquisitions: Teva Pharmaceutical Industries Ltd.’s $40 billion deal to buy Allergan plc’s generics business and Mylan N.V.’s $9.9 billion deal to acquire Meda AB. Teva said that with the FTC’s acceptance of the proposed consent order, the company has satisfied
HYDERABAD, India, and PRINCETON, N.J. — Dr. Reddy’s Laboratories plans to buy eight Abbreviated New Drug Applications (ANDAs) in the United States from Teva Pharmaceutical Industries Ltd. and an affiliate of Allergan plc for $350 million in cash. Dr. Reddy’s, which announced the agreement over the weekend, said the acquired products are being divested by
NEW YORK — Mylan N.V. and Teva Pharmaceutical Industries Ltd. have rolled out norgestimate/ethinyl estradiol tablets, a birth control pill, in the United States. The companies said Tuesday that their products are generic versions of Janssen Pharmaceuticals Inc.’s Ortho Tri-Cyclen Lo tablets. Mylan said its norgestimate/ethinyl estradiol tablets — available in dosages of 0.18 mg/0.025
NEW YORK — Mylan N.V. and Teva Pharmaceutical Industries Ltd. have released guanfacine extended-release tablets, a nonstimulant medication for attention deficit hyperactivity disorder (ADHD), in the United States. The pharmaceutical companies said Tuesday that their products, available in strengths of 1 mg, 2 mg, 3 mg and 4 mg, are generic equivalents of Intuniv from
NEW YORK — For the second time this week, Perrigo Co. plc has rejected an acquisition offer from Mylan N.V. On Friday morning, Mylan announced a formal offer to buy Perrigo for $60 per share in cash and 2.2 Mylan ordinary shares for each Perrigo ordinary share. Based on the prior day’s close, the deal
